L. Mandelbrot, R. Tubiana, L. Chenadec, J. Dollfus, C. et al., No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, vol.61, pp.1715-1740, 2015.

P. Morlat,

L. M. Mofenson, In-utero ART exposure and the need for pharmacovigilance. The Lancet Global health, vol.6, p.29880311, 2018.

A. L. Slogrove, P. Clayden, and E. J. Abrams, Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding, Curr Opin HIV AIDS, vol.12, issue.4, p.28426519, 2017.

J. M. Lewis, E. Railton, A. Riordan, S. Khoo, and M. Chaponda, Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing, Aids, vol.30, issue.8, p.27128333, 2016.

N. Mulligan, . Bb, E. Capparelli, and A. Stek, Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women. CROI

M. A. Boston and U. ,

J. B. Pain, M. P. Le, M. Caseris, C. Amiel, L. Lassel et al., Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Antimicrob Agents Chemother, vol.59, p.25845873, 2015.

B. H. Rimawi, J. E. Rajakumar, A. Tao, S. Jiang, Y. Gillespie et al., Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy, Antimicrob Agents Chemother, issue.6, p.61, 2017.

S. Schalkwijk, R. Greupink, A. P. Colbers, A. C. Wouterse, V. G. Verweij et al., Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model, The Journal of antimicrobial chemotherapy, vol.71, issue.2, pp.480-483, 2016.

R. Zash, D. L. Jacobson, M. Diseko, G. Mayondi, M. Mmalane et al., Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. The Lancet Global health, vol.6, p.29880310, 2018.

M. Schomaker, M. A. Davies, M. Cornell, and N. Ford, Assessing the risk of dolutegravir for women of childbearing potential. The Lancet Global health, vol.6, p.30049617, 2018.

L. The, Dolutegravir for HIV: a lesson in pregnancy safety research, Lancet, vol.391, p.2296, 2018.

L. Gavard, D. Beghin, F. Forestier, Y. Cayre, G. Peytavin et al., Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs, Eur J Obstet Gynecol Reprod Biol, vol.147, issue.2, p.19773109, 2009.

P. F. Ceccaldi, C. Ferreira, L. Gavard, S. Gil, G. Peytavin et al., Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model, Am J Obstet Gynecol, vol.198, issue.4, pp.433-434, 2008.

P. Bapat, L. S. Pinto, A. Lubetsky, H. Berger, and G. Koren, Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am J Obstet Gynecol, vol.213, issue.5, pp.710-711, 2015.

P. Berveiller, O. Mir, C. Vinot, C. Bonati, P. Duchene et al., Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model, Am J Obstet Gynecol, vol.206, issue.1, pp.92-93, 2012.

D. Sousa-mendes, M. Lui, G. Zheng, Y. Pressiat, C. Hirt et al., A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways, Clinical pharmacokinetics, 2016.

J. A. Smith, A. Gaikwad, S. Mosley, . Coffer-l-2nd, J. Cegelski et al., Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy, Am J Obstet Gynecol, vol.210, issue.3, pp.275-276, 2014.

J. Zhang, S. Hayes, B. M. Sadler, I. Minto, J. Brandt et al., Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients, Br J Clin Pharmacol, vol.80, issue.3, p.25819132, 2015.

V. Faure-bardon, L. Mandelbrot, D. Duro, C. Dussaux, M. Le et al., Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model, Aids, vol.32, issue.3, p.29112064, 2018.

L. Gavard, S. Gil, G. Peytavin, P. F. Ceccaldi, C. Ferreira et al., Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol, vol.195, issue.1, p.16678781, 2006.

P. F. Ceccaldi, L. Gavard, L. Mandelbrot, E. Rey, R. Farinotti et al., Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model, Obstetrics and gynecology international, p.726593, 2009.

L. Mandelbrot, D. Duro, E. Belissa, and G. Peytavin, Placental transfer of darunavir in an ex vivo human cotyledon perfusion model, Antimicrob Agents Chemother, vol.58, issue.9, p.24982090, 2014.

J. C. Challier, D. 'athis, P. Guerre-millo, M. Nandakumaran, and M. , Flow-dependent transfer of antipyrine in the human placenta in vitro, Reprod Nutr Dev, vol.23, issue.1, p.6221374, 1983.
URL : https://hal.archives-ouvertes.fr/hal-00898027

H. Schneider, M. Panigel, and J. Dancis, Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am J Obstet Gynecol, vol.114, issue.6, p.4676572, 1972.

C. Vinot, L. Gavard, J. M. Treluyer, S. Manceau, E. Courbon et al., Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression, Antimicrob Agents Chemother, vol.57, issue.3, p.23295922, 2013.

L. Mandelbrot, D. Duro, E. Belissa, and G. Peytavin, Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model, Antimicrob Agents Chemother, vol.59, issue.5, p.25691637, 2015.

B. H. Jung, N. L. Rezk, A. S. Bridges, A. H. Corbett, and A. D. Kashuba, Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, vol.21, issue.10, p.17582235, 2007.

M. L. Cottrell, T. Hadzic, and A. D. Kashuba, Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir, Clinical pharmacokinetics, vol.52, issue.11, p.23824675, 2013.

, Dolutegravir, CID = 54726191

F. Fauchet, J. M. Treluyer, S. M. Illamola, C. Pressiat, G. Lui et al., Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment, Antimicrob Agents Chemother, vol.59, issue.9, p.26149996, 2015.

L. Gavard, S. Gil, G. Peytavin, P. Ceccaldi, C. Ferreira et al., Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol, vol.195, issue.1, p.16678781, 2006.

C. Vinot, J. M. Treluyer, C. Giraud, L. Gavard, G. Peytavin et al., Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob Agents Chemother, vol.60, issue.5, p.26833154, 2016.

P. Berveiller, C. Vinot, O. Mir, S. Broutin, A. Deroussent et al., Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model, Am J Obstet Gynecol, vol.207, issue.6, pp.514-515, 2012.

L. Mandelbrot, R. Tubiana, L. Chenadec, J. Dollfus, C. Faye et al., No Perinatal Transmission of HIV-1 in Women Efficiently Treated Since Conception, CROI, 2015.

W. Seattle, , p.2015

J. Sibiude, J. Warszawski, and S. Blanche, Tolerance of the newborn to antiretroviral drug exposure in utero, Expert opinion on drug safety, vol.14, issue.5, p.25727366, 2015.

L. M. Mofenson, Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant in the Room?, J Infect Dis, vol.213, issue.7, p.26265779, 2016.